Is there cross-toxicity between nevirapine and efavirenz in subjects developing rash? [4]

AIDS

Volumn 14, Issue 11, 2000, Pages 1672-1673

  Soriano, V ^a   Dona, C ^a   Barreiro, P ^a   Gonzalez Lahoz, J ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; NEVIRAPINE;

CASE REPORT; DRUG CROSS REACTIVITY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERSENSITIVITY REACTION; LETTER; LYMPHOCYTE COUNT; NEUROLOGIC DISEASE; PRIORITY JOURNAL; RASH; SKIN TOXICITY; VIRUS LOAD;

ANTI-HIV AGENTS; DRUG ERUPTIONS; EXANTHEMA; HIV INFECTIONS; HUMANS; NEVIRAPINE; OXAZINES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0033816765     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200007280-00032     Document Type: Letter

References (4)

1. Efavirenz associated with corticosteroids in patients with previous severe hypersensitivity reaction due to nevirapine
2. A randomized double-blind trial comparing combinations of nevirapine, didanosine and zidovudine for HIV-1 infected patients: The INCAS trial
3. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIVB-1 infection in adults. Study 006 Team
4. Efavirenz